Oxford Biomedica and Sigma-Aldrich win key ruling in open biosystems patent infringement dispute

29-Oct-2007

Oxford BioMedica and Sigma-Aldrich announced that they received a key order confirming the strength and validity of intellectual property owned by Oxford BioMedica and licensed exclusively in the research field to Sigma-Aldrich. The ruling was part of the construction of patent claim terms in the patent infringement suit brought against Open Biosystems, Inc.

The lawsuit, which is pending in the U.S. District Court for the Eastern District of Missouri, alleges that Open Biosystems infringes U.S. Patent Nos. 6,924,123 and 7,056,699 entitled Lentiviral LTR Deleted Vector, which are owned by Oxford BioMedica and exclusively licensed to Sigma-Aldrich for research use, by selling, among other products, Open Biosystems' Lentiviral shRNAmir Library. In his order U.S. District Judge Charles A. Shaw concluded "that the constructions of the disputed terms and phrases proposed by plaintiff are correct."

Other news from the department politics & laws

Most read news

More news from our other portals

Fighting cancer: latest developments and advances